Background: Migraine is a disabling neuroinflammatory condition characterized by increasing
the levels of interleukin (IL)-6, a proinflammatory cytokine and C-reactive protein (CRP)
which considered as a vascular inflammatory mediator, disrupting the integrity of blood-brain barrier
and contributing to neurogenic inflammation, and disease progression. Curcumin and ω-3 fatty acids
can exert neuroprotective effects through modulation of IL-6 gene expression and CRP levels. The aim
of present study is the evaluation of combined effects of ω-3 fatty acids and nano-curcumin supplementation
on IL-6 gene expression and serum level and hs-CRP levels in migraine patients.
Methods: Eighty episodic migraine patients enrolled in the trial and were divided into four groups as 1)
combination of ω-3 fatty acids (2500 mg) plus nano-curcumin (80 mg), 2) ω-3 (2500 mg), 3) nanocurcumin
(80 mg), and 4) the control (ω-3 and nano-curcumin placebo included oral paraffin oil) over
a two-month period. At the beginning and the end of the study, the expression of IL-6 from peripheral
blood mononuclear cells and IL-6 and hs-CRP serum levels were measured, using a real-time PCR and
ELISA methods, respectively.
Results: The results showed that both of ω-3 and nano-curcumin down-regulated IL-6 mRAN and significantly
decreased the serum concentration. hs-CRP serum levels significantly decrease in combination
and nano-curcumin within groups (P<0.05). An additive greater reduction of IL-6 and hs-CRP
was observed in the combination group suggested a possible synergetic relation.
Conclusion: It seems that ω-3 fatty acids and curcumin supplementation can be considered a new
promising target in migraine prevention.